Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 15/20 | 0.59 |
| ▸ | PTPN5 | P54829 | 15/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | EDNRB | P24530 | 1/20 | 0.49 |
| ▸ | EDNRA | P25101 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 5/20 | 0.48 |
| ▸ | HSPE1 | P61604 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618169 | 0.91 | HSD11B1 (0.51) | PTPN1PTPN2PTPN5HSD11B1EDNRB | |
| SCHEMBL27422029 | 0.82 | MEN1 (0.56) | PTPN1PTPN2PTPN5ACLYHSPD1 | |
| SCHEMBL616005 | 0.82 | FBP1 (0.65) | PTPN1PTPN2PTPN5ACLYHSPD1 | |
| SCHEMBL4881258 | 0.82 | PTPN2 (0.55) | PTPN1PTPN2PTPN5EDNRBEDNRA | |
| SCHEMBL4509303 | 0.81 | AGPAT2 (0.59) | PTPN1PTPN2PTPN5 | |
| SCHEMBL5337088 | 0.81 | HSD11B1 (0.50) | PTPN1PTPN2PTPN5HSD11B1EDNRB | |
| SCHEMBL5338606 | 0.81 | HSD11B1 (0.55) | PTPN1PTPN2PTPN5HSD11B1EDNRB | |
| SCHEMBL5339534 | 0.79 | EDNRA (0.52) | PTPN1PTPN2PTPN5HSD11B1EDNRB | |
| SCHEMBL614790 | 0.79 | PKM (0.56) | PTPN1PTPN2PTPN5HSD11B1EDNRB | |
| SCHEMBL5343634 | 0.78 | EDNRB (0.53) | PTPN1PTPN2PTPN5HSD11B1EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | PTPN1 1291/4885PTPN2 1870/4885PTPN5 1376/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | PTPN1 2480/4885PTPN2 2822/4885PTPN5 2696/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | PTPN1 2480/4885PTPN2 2822/4885PTPN5 2696/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | PTPN1 3194/4885PTPN2 3275/4885PTPN5 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.